Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Simple item page
dc.contributor.authorSigounas, George
dc.contributor.authorMehlhop, Paul
dc.date.accessioned2019-11-11T18:37:56Z
dc.date.available2019-11-11T18:37:56Z
dc.date.issued2002-10-17
dc.descriptionApplication abandoned?en_US
dc.description.abstractA method of reducing organ toxicity in a subject being administered a cytotoxic agent comprising concurrently administering with the cytotoxic agent erythropoietin (EPO), the EPO being administered in an amount effective to reduce pulmonary toxicity caused by the cytotoxic agent.en_US
dc.identifier.otherCanada Patent # CA2443025A1
dc.identifier.otherUS Pat# US28262101P
dc.identifier.urihttp://hdl.handle.net/10342/7535
dc.language.isoen_USen_US
dc.relation.urihttps://patents.google.com/patent/CA2443025A1/en?oq=inassignee:%22East+Carolina%22en_US
dc.subjectcytotoxicityen_US
dc.titleErythropoietin ameliorates chemotherapy-induced toxicity in vivoen_US
dc.typePatenten_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CA2443025A1.pdf
Size:
741.62 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Biochemistry and Molecular Biology